Increased haemoglobin (Hb) is called erythrocytosis or polycythaemia. It may reflect too little plasma fluid, or a true increase in red blood cells. The distinction matters because treatment depends on the cause.
Causes
1. Relative increase: dehydration
Red-cell mass is normal, but blood is concentrated due to reduced plasma volume.
- Not drinking enough fluids
- Vomiting or diarrhoea
- Excessive sweating
- Diuretic medicines
This is often temporary. Robbins Basic Pathology describes this as relative polycythaemia from reduced plasma volume. - Robbins & Kumar Basic Pathology, p. 398
2. Secondary erythrocytosis: the body responds to low oxygen or excess erythropoietin (EPO)
Low-oxygen causes
- Smoking, including carbon monoxide exposure
- Obstructive sleep apnoea
- COPD or other chronic lung disease
- Severe obesity-hypoventilation
- Cyanotic congenital heart disease or right-to-left cardiac shunt
- Living or prolonged stays at high altitude
Excess EPO production
- Kidney disease, renal artery narrowing, renal cysts, or after kidney transplantation
- Rare EPO-producing tumours, particularly renal-cell carcinoma, hepatocellular carcinoma, and cerebellar haemangioblastoma
- Rare inherited high-oxygen-affinity haemoglobin variants
Medication or substance related
- Testosterone or anabolic steroids
- EPO injections or blood doping
- SGLT2 inhibitors used for diabetes or heart/kidney disease
- Some cancer drugs, including certain tyrosine-kinase inhibitors
The
Merck evaluation guidance lists oxygen saturation, serum EPO, and P50 testing as key parts of investigating isolated erythrocytosis. -
Robbins & Kumar Basic Pathology, p. 398
3. Primary erythrocytosis: polycythaemia vera (PV)
This is a bone-marrow blood cancer, usually driven by a JAK2 mutation. It can also raise white cells and platelets. Symptoms may include headaches, dizziness, blurred vision, itching after a hot bath, burning/red hands or feet, enlarged spleen, and blood clots.
How it is treated
| Cause | Main treatment |
|---|
| Dehydration | Rehydrate and treat vomiting, diarrhoea, or medication-related fluid loss. Repeat the blood count. |
| Smoking or carbon monoxide | Stop smoking and investigate possible carbon monoxide exposure. |
| Sleep apnoea | Sleep assessment and CPAP if confirmed; weight management where relevant. |
| Lung or heart disease | Treat the underlying condition. Long-term oxygen may be used when clinically indicated. |
| High altitude | Usually no treatment if temporary and asymptomatic; returns toward normal after descent/acclimatisation. |
| Testosterone, EPO, anabolic steroids, SGLT2 inhibitor, etc. | Do not stop a prescribed drug on your own. The prescriber should review dose, need, alternatives, and monitoring. |
| Kidney disorder or EPO-producing tumour | Treat the renal condition or tumour with the appropriate specialist team. |
| Polycythaemia vera | Haematology care, blood removal (venesection/phlebotomy), usually low-dose aspirin if safe, and sometimes medicines to lower blood-cell production. |
For secondary erythrocytosis, treatment is usually directed at the cause. Oxygen therapy can help hypoxia-related cases; venesection is generally reserved for significant symptoms of hyperviscosity or selected severe elevations, because the higher Hb may be compensating for chronic low oxygen. In PV, phlebotomy and medication are used to reduce clot risk, as summarized in the
Merck PV overview.
What tests are commonly needed
A clinician will generally repeat the full blood count while well hydrated, then consider:
- Oxygen saturation, sometimes blood gas or overnight sleep testing
- Serum EPO level
- JAK2 mutation testing if PV is suspected
- Kidney and liver tests, urinalysis, and targeted imaging if indicated
- Review of smoking, altitude exposure, supplements, testosterone, EPO, and medications
Seek urgent care now if
There is a high Hb/haematocrit plus possible clot symptoms: sudden weakness or facial droop, trouble speaking, chest pain, shortness of breath, coughing blood, one-sided leg swelling/pain, new severe headache, fainting, or visual loss.
A recent systematic review also highlights drug-induced erythrocytosis, especially with testosterone and SGLT2 inhibitors, as an important modern cause (
Liu et al., 2025).